TRACON to Report Third Quarter Company Highlights and Financial Results on November 7, 2017
Conference call and webcast: | |
Date: | November 7, 2017 |
Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
Passcode: | 7458759 |
Via web: | www.traconpharma.com; “Events and Presentation” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with
Company Contact:
Chief Business Officer
(858) 550-0780 ext. 236
clogan@traconpharma.com
Investor Contact:
Andrew McDonald
646-597-6987
Andrew@lifesciadvisors.com